The purpose of this narrative review is to bring together the most recent epidemiologic,
preclinical, and clinical findings to offer our perspective on best practices for managing …

This review critically appraises the published microbiologic and clinical data on the
treatment of patients with carbapenem‐resistant Acinetobacter baumannii infections …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …

Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Carbapenem-resistant Acinetobacter baumannii (CRAB) constitutes an increasing problem
worldwide. CRAB bacteremia is associated with a high fatality rate and its optimal treatment …

Carbapenem-resistant Acinetobacter baumannii (CRAB) has been classified by the World
Health Organization as being in the critical category of pathogens requiring urgent new …

Objectives This study aimed to assess the effectiveness of trimethoprim–sulfamethoxazole
(TMP/SMX) as monotherapy for the treatment of carbapenem-resistant Acinobacter …

Background No clear evidence supports the use of cefiderocol as first line treatment in A.
baumannii infections. Methods We conducted an observational retrospective/prospective …

Acinetobacter baumannii is a drug-resistant Gram-negative pathogen increasingly causing
hospital-acquired infections in critically ill patients. In this review, we summarize the current …